Non-V600E <i>BRAF</i> mutations and treatment for hairy cell leukemia
Abstract
Abstract We found 20 patients with an immunophenotype consistent with classic hairy cell leukemia and BRAF mutations other than just V600E. Fourteen had 1 non-V600E BRAF mutation and 6 had V600E with 1 (n = 5) or 2 (n = 1) non-V600E BRAF comutations. This study was registered at https://clinicaltrials.gov as #NCT01087333.
Article Details
Authors (19)
Evgeny Arons
3Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Chin-Hsien Tai
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Joshi Suraj
2Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Yuelin Liu
Chi-Ping Day
Mark Raffeld
Department of Pathology, NCI, Bethesda, MD
Liqiang Xi
2Laboratory of Pathology, Clinical Center, National Institutes of Health, Bethesda, MD
Hong Zhou
Shanghai Collaborative Innovation Center of Agri-Seeds, School of Agriculture and Biology, Shanghai Jiao Tong University
Mory Gould
1National Cancer Institute, Laboratory Of Molecular Biology, Bethesda, United States
Isaac Shpilman
1National Cancer Institute, Laboratory Of Molecular Biology, Bethesda, United States
Cristopher C. Oakes
5Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
Seema Bhat
1The Ohio State University, Internal Medicine, Columbus, United States
Michael Grever
1The Ohio State University, Columbus, United States
Daniel Jones
Department of Cell and Molecular Biology
Kerry Rogers
1The Ohio State University, Internal Medicine, Columbus, United States
Hao-Wei Wang
Constance M. Yuan
2Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
Cenk Sahinalp
1National Cancer Institute, Laboratory Of Molecular Biology, Bethesda, United States
Robert J. Kreitman
3Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD